Is Selank safe?
Based on available human and animal research, Selank appears to have a favourable safety profile. Clinical trials evaluating Selank in individuals with generalised anxiety disorder (GAD) and neurasthenia have demonstrated anxiolytic effects comparable to conventional anti-anxiety medications, while limiting many of the side effects often associated with benzodiazepines, such as excessive drowsiness or cognitive impairment [1]. Scientific reviews on Selank's pharmacology also describe it as a peptide with relatively low toxicity and good tolerability in research settings [2].
However, it should be emphasised that most published studies have been relatively small, and many were conducted in Russia. Larger international clinical trials are needed to better assess its long-term safety profile.
Is the peptide Selank safe?
Current evidence suggests that Selank is generally well tolerated in scientific studies. Unlike benzodiazepines, which directly activate specific receptor sites, Selank appears to modulate several biological systems related to mood, stress response, and cognitive functions. Studies indicate it may affect GABA signalling, enkephalin metabolism, neurotrophic pathways, and immunological mechanisms without inducing strong sedative effects [2–4].
Animal studies have also shown that Selank does not disrupt normal activity and may even reduce sedation when used with certain anxiolytic substances [5]. However, data regarding long-term safety in humans remain limited.
Is Selank dangerous?
Currently published research does not suggest Selank to be inherently dangerous when used in controlled research settings. Clinical trials have generally reported good tolerability and a low incidence of adverse effects [1,2].
At the same time, a lack of reported safety issues should not be interpreted as proof of complete safety. As long-term human studies remain limited, researchers continue to analyse Selank's impact on neurotransmitters, neuroplasticity, and immune system function. As with any research peptide, caution should be exercised when interpreting claims regarding safety.
Side Effects of Selank
Compared to many traditional anxiolytics, Selank is associated with a relatively small number of reported adverse effects. Scientific reviews often highlight the absence of significant sedation, muscle relaxation, cognitive impairment, or the development of dependence, which are frequently observed with benzodiazepine use [1,2].
Some publications concerning peptides mention mild and transient nasal irritation following intranasal administration. However, serious adverse events were not frequently reported in the available studies. Due to the limited number of studies, the occurrence of rare or atypical side effects cannot be entirely ruled out.
Can Selank cause anxiety?
The main area of research into Selank is anxiety reduction, not its induction. Studies involving individuals with generalised anxiety disorder have shown improvements in anxiety symptoms, while animal studies have consistently demonstrated a reduction in anxiety-related behaviours [1,6].
No significant studies have identified anxiety as a common side effect. However, it is important to note that individual responses to neuroactive compounds can vary, and some individuals may experience unexpected emotional or mood changes. These have not been recognised as typical findings in scientific literature, though.
Can Selank cause insomnia?
Current research does not indicate insomnia as a frequent side effect of Selank. Some researchers suggest that Selank's impact on stress regulation and emotional balance may indirectly support healthy sleep patterns [7].
However, formal studies of sleep remain limited. Given that Selank may affect neurotransmitter systems associated with vigilance and cognitive functions, individual responses may vary. Based on current data, insomnia does not appear to be a frequently reported effect.
Does Selank Cause Hair Loss?
Currently, there is no published scientific evidence linking Selank to hair loss. Clinical, experimental, and mechanistic studies have primarily focused on GABA signalling, enkephalin metabolism, neurotrophic factors, and immune regulation, rather than hair growth pathways or androgenic activity [2–4].
Selank does not currently have any scientific research suggesting it contributes to hair loss or accelerated hair shedding.
Does Selank cause addiction?
One of the most frequently discussed advantages of Selank is its apparent lack of addictive properties. Unlike benzodiazepines, which directly activate benzodiazepine receptors and can lead to tolerance and physical dependence, Selank appears to act through other biological pathways related to GABA modulation, endogenous opioid peptides, and neurotrophic signalling [2,3].
In published clinical and experimental studies, no evidence of addiction, compulsive use, or drug-seeking behaviours has been reported. However, it should be noted that the number of long-term studies remains limited compared to approved anti-anxiety medications.
Bupropion withdrawal symptoms
Current research has not identified a recognised withdrawal syndrome associated with Selank. Clinical studies and scientific reviews do not describe recurrent anxiety, physical dependence or withdrawal symptoms similar to those observed with benzodiazepines [1,2].
However, due to the limited number of long-term studies, the lack of documented withdrawal symptoms should not be interpreted as definitive proof that such effects can never occur.
Does Selank Cause Euphoria?
The available data suggests that Selank is not a euphoriant or intoxicating substance. Research has primarily focused on its anxiolytic, cognitive-enhancing, and neuroregulatory properties, rather than on recreational or psychoactive effects [1–4].
Scientists typically describe Selank as a peptide that supports emotional stability and reduces anxiety without causing euphoria, intoxication, or altered states of consciousness characteristic of recreational substances.
Is Selank detected in drug tests?
Currently, there is no evidence to suggest that Selank is included in standard drug tests used in workplaces, the military, or routine toxicological diagnostics. Typical tests are designed to detect substances such as opioids, cannabinoids, cocaine metabolites, amphetamines, and benzodiazepines.
Since Selank is a synthetic peptide and does not belong to commonly tested groups of substances, it is not usually included in routine tests. However, specialised laboratory analyses targeting peptides may be possible in research, forensic, or anti-doping environments.
Summary
Current research suggests that Selank has a favourable safety profile and is generally well tolerated under controlled research conditions. Studies have demonstrated low toxicity, minimal sedative effects, and a lack of dependence-forming effects compared to many traditional anxiolytic drugs. Common issues such as hair loss, significant withdrawal symptoms, or narcotic effects have also not been identified.
Despite promising results, the available clinical database remains relatively small. Further research involving larger participant groups is needed to better assess long-term safety, rare adverse events, and effects across different populations.
Disclaimer
This article is for educational and informational purposes only. Selank remains a research peptide in many countries, and scientific knowledge regarding its long-term safety is constantly evolving. The information presented is a summary of preclinical, clinical, and mechanistic research findings and should not be interpreted as medical advice, a therapeutic recommendation, or an endorsement of safety or efficacy.
For research purposes only: Selank products available from Semax Polska are intended solely for laboratory and scientific research. They are not authorised for human consumption or for use for medical, diagnostic, therapeutic or prophylactic purposes. All research materials should be used in accordance with applicable legislation and laboratory testing standards.
References
[1] Zozulia, A. A., Neznamov, G. G., Siuniakov, T. S., Kost, N. V., Gabaeva, M. V., Sokolov, O. Y., Serebriakova, E. V., Siranchieva, O. A., Andriushenko, A. V., Telesheva, E. S., Siuniakov, S. A., Smulevich, A. B., Myasoedov, N. F., & Seredenin, S. B. (2008). Efficacy and Possible Mechanisms of Action of a New Peptide Anxiolytic Selank in the Therapy of Generalised Anxiety Disorders and Neurasthenia. Journal of Neurology and Psychiatry named after S.S. Korsakov, 108(4), 38–48. https://pubmed.ncbi.nlm.nih.gov/18454096/
[2] Vyunova, T. V., Andreeva, L., Shevchenko, K., & Myasoedov, N. F. (2018). Peptide-Based Anxiolytics: The Molecular Aspects of Heptapeptide Selank Biological Activity. Protein and Peptide Letters, 25(10), 914–923. https://doi.org/10.2174/0929866525666180925144642
[3] Zozulya, A. A., Kost, N. V., Sokolov, O. Y., Gabaeva, M. V., Grivennikov, I. A., Andreeva, L. N., Zolotarev, Y. A., Ivanov, S. V., Andryushchenko, A. V., Myasoedov, N. F., & Smulevich, A. B. (2001). The Inhibitory Effect of Selank on Enkephalin-Degrading Enzymes as a Possible Mechanism of Its Anxiolytic Activity. Bulletin of Experimental Biology and Medicine, 131(4), 315–317. https://doi.org/10.1023/A:1017979514274
[4] Levitskaya, N. G., Andreeva, L. A., Mezentseva, M. V., Shapoval, I. M., Podchernyaeva, R. Y., Shcherbenko, V. E., Potapova, L. A., Russu, L. I., Ershov, F. I., & Myasoedov, N. F. (2010). Intranasal Administration of the Peptide Selank Regulates BDNF Expression in the Rat Hippocampus In Vivo. Doklady Biological Sciences, 431, 79–82.
[5] Kost, N. V., Sokolov, O. Y., Zozulya, S. A., & Myasoedov, N. F. (2025). Combined Action of Benzodiazepine Tranquillisers and Peptide Anxiolytic Selank in BALB/c Mice. Neurochemical Journal, 19, 743–748. https://doi.org/10.1134/S1819712425700783
[6] Czabak-Garbacz, R., Cygan, B., Wolański, Ł., & Kozlovsky, I. (2006). Influence of Long-Term Treatment with Tuftsin Analogue TP-7 on Anxiety-Phobic States and Body Weight. Pharmacological Reports, 58(4), 562–567. PMID: 16963804.
[7] Vitiello, M. V., Schwartz, R. S., Moe, K. E., Mazzoni, G., & Merriam, G. R. (2001). Treating Age-Related Changes in Somatotrophic Hormones, Sleep, and Cognition. Dialogues in Clinical Neuroscience, 3(3), 229–236. https://doi.org/10.31887/DCNS.2001.3.3/mvvitiello